BindingDB logo
myBDB logout

BDBM50270069 CHEMBL499438::TPQRARRRKKRY

SMILES: [#6]-[#6@@H](-[#8])-[#6@H](-[#7])-[#6](=O)-[#7]-1-[#6]-[#6]-[#6]-[#6@H]-1-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6](-[#7])=O)-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]-[#6]-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]-[#6]-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-c1ccc(-[#8])cc1)-[#6](-[#8])=O

InChI Key: InChIKey=GBWNVGJPAAAKFV-XVVOLBHMSA-N

Data: 5 KI

Find this compound or compounds like it in BindingDB or PDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 5 hits for monomerid = 50270069   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kcal/mole
IC50
nM
Kd
nM
EC50/IC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
Homo sapiens furin (paired basic amino acid cleaving enzyme) (FURIN), mRNA


(Homo sapiens (Human))
BDBM50270069
PNG
(CHEMBL499438 | TPQRARRRKKRY)
Show SMILES [#6]-[#6@@H](-[#8])-[#6@H](-[#7])-[#6](=O)-[#7]-1-[#6]-[#6]-[#6]-[#6@H]-1-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6](-[#7])=O)-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]-[#6]-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]-[#6]-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-c1ccc(-[#8])cc1)-[#6](-[#8])=O |r|
Show InChI InChI=1S/C68H122N30O16/c1-36(88-53(103)42(15-7-29-83-64(73)74)92-60(110)47(25-26-50(71)101)96-61(111)49-20-12-34-98(49)62(112)51(72)37(2)99)52(102)89-43(16-8-30-84-65(75)76)56(106)93-45(18-10-32-86-67(79)80)58(108)94-44(17-9-31-85-66(77)78)57(107)91-40(13-3-5-27-69)54(104)90-41(14-4-6-28-70)55(105)95-46(19-11-33-87-68(81)82)59(109)97-48(63(113)114)35-38-21-23-39(100)24-22-38/h21-24,36-37,40-49,51,99-100H,3-20,25-35,69-70,72H2,1-2H3,(H2,71,101)(H,88,103)(H,89,102)(H,90,104)(H,91,107)(H,92,110)(H,93,106)(H,94,108)(H,95,105)(H,96,111)(H,97,109)(H,113,114)(H4,73,74,83)(H4,75,76,84)(H4,77,78,85)(H4,79,80,86)(H4,81,82,87)/t36-,37+,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,51-/m0/s1
PDB

KEGG

UniProtKB/SwissProt
UniProtKB/TrEMBL

B.MOAD
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
47n/an/an/an/an/an/an/an/a



Institute for Medical Research

Curated by ChEMBL


Assay Description
Inhibition of human recombinant furin assessed as fluorescent Pyr-RTKR-AMC substrate cleavage


J Biol Chem 282: 20847-53 (2007)


Article DOI: 10.1074/jbc.M703847200
BindingDB Entry DOI: 10.7270/Q2057FPB
More data for this
Ligand-Target Pair
Subtilisin/kexin type 4


(Homo sapiens (Human))
BDBM50270069
PNG
(CHEMBL499438 | TPQRARRRKKRY)
Show SMILES [#6]-[#6@@H](-[#8])-[#6@H](-[#7])-[#6](=O)-[#7]-1-[#6]-[#6]-[#6]-[#6@H]-1-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6](-[#7])=O)-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]-[#6]-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]-[#6]-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-c1ccc(-[#8])cc1)-[#6](-[#8])=O |r|
Show InChI InChI=1S/C68H122N30O16/c1-36(88-53(103)42(15-7-29-83-64(73)74)92-60(110)47(25-26-50(71)101)96-61(111)49-20-12-34-98(49)62(112)51(72)37(2)99)52(102)89-43(16-8-30-84-65(75)76)56(106)93-45(18-10-32-86-67(79)80)58(108)94-44(17-9-31-85-66(77)78)57(107)91-40(13-3-5-27-69)54(104)90-41(14-4-6-28-70)55(105)95-46(19-11-33-87-68(81)82)59(109)97-48(63(113)114)35-38-21-23-39(100)24-22-38/h21-24,36-37,40-49,51,99-100H,3-20,25-35,69-70,72H2,1-2H3,(H2,71,101)(H,88,103)(H,89,102)(H,90,104)(H,91,107)(H,92,110)(H,93,106)(H,94,108)(H,95,105)(H,96,111)(H,97,109)(H,113,114)(H4,73,74,83)(H4,75,76,84)(H4,77,78,85)(H4,79,80,86)(H4,81,82,87)/t36-,37+,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,51-/m0/s1
KEGG

UniProtKB/SwissProt
UniProtKB/TrEMBL

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
624n/an/an/an/an/an/an/an/a



Institute for Medical Research

Curated by ChEMBL


Assay Description
Inhibition of human recombinant PC4 assessed as fluorescent Pyr-RTKR-AMC substrate cleavage


J Biol Chem 282: 20847-53 (2007)


Article DOI: 10.1074/jbc.M703847200
BindingDB Entry DOI: 10.7270/Q2057FPB
More data for this
Ligand-Target Pair
Subtilisin/kexin type 5


(Homo sapiens (Human))
BDBM50270069
PNG
(CHEMBL499438 | TPQRARRRKKRY)
Show SMILES [#6]-[#6@@H](-[#8])-[#6@H](-[#7])-[#6](=O)-[#7]-1-[#6]-[#6]-[#6]-[#6@H]-1-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6](-[#7])=O)-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]-[#6]-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]-[#6]-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-c1ccc(-[#8])cc1)-[#6](-[#8])=O |r|
Show InChI InChI=1S/C68H122N30O16/c1-36(88-53(103)42(15-7-29-83-64(73)74)92-60(110)47(25-26-50(71)101)96-61(111)49-20-12-34-98(49)62(112)51(72)37(2)99)52(102)89-43(16-8-30-84-65(75)76)56(106)93-45(18-10-32-86-67(79)80)58(108)94-44(17-9-31-85-66(77)78)57(107)91-40(13-3-5-27-69)54(104)90-41(14-4-6-28-70)55(105)95-46(19-11-33-87-68(81)82)59(109)97-48(63(113)114)35-38-21-23-39(100)24-22-38/h21-24,36-37,40-49,51,99-100H,3-20,25-35,69-70,72H2,1-2H3,(H2,71,101)(H,88,103)(H,89,102)(H,90,104)(H,91,107)(H,92,110)(H,93,106)(H,94,108)(H,95,105)(H,96,111)(H,97,109)(H,113,114)(H4,73,74,83)(H4,75,76,84)(H4,77,78,85)(H4,79,80,86)(H4,81,82,87)/t36-,37+,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,51-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
649n/an/an/an/an/an/an/an/a



Institute for Medical Research

Curated by ChEMBL


Assay Description
Inhibition of human recombinant PC5/6 assessed as fluorescent Pyr-RTKR-AMC substrate cleavage


J Biol Chem 282: 20847-53 (2007)


Article DOI: 10.1074/jbc.M703847200
BindingDB Entry DOI: 10.7270/Q2057FPB
More data for this
Ligand-Target Pair
Proprotein convertase subtilisin/kexin type 6


(Rattus norvegicus)
BDBM50270069
PNG
(CHEMBL499438 | TPQRARRRKKRY)
Show SMILES [#6]-[#6@@H](-[#8])-[#6@H](-[#7])-[#6](=O)-[#7]-1-[#6]-[#6]-[#6]-[#6@H]-1-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6](-[#7])=O)-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]-[#6]-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]-[#6]-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-c1ccc(-[#8])cc1)-[#6](-[#8])=O |r|
Show InChI InChI=1S/C68H122N30O16/c1-36(88-53(103)42(15-7-29-83-64(73)74)92-60(110)47(25-26-50(71)101)96-61(111)49-20-12-34-98(49)62(112)51(72)37(2)99)52(102)89-43(16-8-30-84-65(75)76)56(106)93-45(18-10-32-86-67(79)80)58(108)94-44(17-9-31-85-66(77)78)57(107)91-40(13-3-5-27-69)54(104)90-41(14-4-6-28-70)55(105)95-46(19-11-33-87-68(81)82)59(109)97-48(63(113)114)35-38-21-23-39(100)24-22-38/h21-24,36-37,40-49,51,99-100H,3-20,25-35,69-70,72H2,1-2H3,(H2,71,101)(H,88,103)(H,89,102)(H,90,104)(H,91,107)(H,92,110)(H,93,106)(H,94,108)(H,95,105)(H,96,111)(H,97,109)(H,113,114)(H4,73,74,83)(H4,75,76,84)(H4,77,78,85)(H4,79,80,86)(H4,81,82,87)/t36-,37+,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,51-/m0/s1
KEGG

UniProtKB/SwissProt

GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
1.02E+3n/an/an/an/an/an/an/an/a



Institute for Medical Research

Curated by ChEMBL


Assay Description
Inhibition of rat PACE4 assessed as fluorescent Pyr-RTKR-AMC substrate cleavage


J Biol Chem 282: 20847-53 (2007)


Article DOI: 10.1074/jbc.M703847200
BindingDB Entry DOI: 10.7270/Q2057FPB
More data for this
Ligand-Target Pair
Subtilisin/kexin type 7


(Homo sapiens (Human))
BDBM50270069
PNG
(CHEMBL499438 | TPQRARRRKKRY)
Show SMILES [#6]-[#6@@H](-[#8])-[#6@H](-[#7])-[#6](=O)-[#7]-1-[#6]-[#6]-[#6]-[#6@H]-1-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6](-[#7])=O)-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]-[#6]-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]-[#6]-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6@@H](-[#6]-c1ccc(-[#8])cc1)-[#6](-[#8])=O |r|
Show InChI InChI=1S/C68H122N30O16/c1-36(88-53(103)42(15-7-29-83-64(73)74)92-60(110)47(25-26-50(71)101)96-61(111)49-20-12-34-98(49)62(112)51(72)37(2)99)52(102)89-43(16-8-30-84-65(75)76)56(106)93-45(18-10-32-86-67(79)80)58(108)94-44(17-9-31-85-66(77)78)57(107)91-40(13-3-5-27-69)54(104)90-41(14-4-6-28-70)55(105)95-46(19-11-33-87-68(81)82)59(109)97-48(63(113)114)35-38-21-23-39(100)24-22-38/h21-24,36-37,40-49,51,99-100H,3-20,25-35,69-70,72H2,1-2H3,(H2,71,101)(H,88,103)(H,89,102)(H,90,104)(H,91,107)(H,92,110)(H,93,106)(H,94,108)(H,95,105)(H,96,111)(H,97,109)(H,113,114)(H4,73,74,83)(H4,75,76,84)(H4,77,78,85)(H4,79,80,86)(H4,81,82,87)/t36-,37+,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,51-/m0/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
1.22E+3n/an/an/an/an/an/an/an/a



Institute for Medical Research

Curated by ChEMBL


Assay Description
Inhibition of human recombinant PC7 assessed as fluorescent Pyr-RTKR-AMC substrate cleavage


J Biol Chem 282: 20847-53 (2007)


Article DOI: 10.1074/jbc.M703847200
BindingDB Entry DOI: 10.7270/Q2057FPB
More data for this
Ligand-Target Pair